CAR T-Cell Therapy In Hematological Malignancies: Staying Ahead Of A Rapidly Evolving Landscape

Content featured by Precision for Medicine

Over the past few years, the approval of two CD19-directed chimeric antigen receptor (CAR) T-cell therapies for B-cell cancers has ignited enthusiasm among researchers and patients for translating this treatment approach to other hematological malignances. Research in the field of CAR T-cell therapies has intensified, as scientists explore ways to increase the impact of these treatments or expand the addressable patient population. Progress is being made in our collective efforts to unlock the full potential of CAR T-cell therapies—whether it is evaluating CAR T-cell therapy as first or second-line treatment; optimizing CAR T-cell therapy for other tumors, both liquid and solid; or innovating in the development or manufacturing of next-generation or off-the-shelf therapies that are safer, more effective, or more accessible for patients, providers, and payers.

In this eBook, we explore the current landscape of CAR T-cell therapies, from real-world data on approved CD19-targeted products to imminent or  emerging treatments for other hematological malignancies. We review the progress, opportunities, and challenges in this space, highlighting key clinical trial data and insights, and mapping out future directions.